Regeneron expands manufacturing capacity through new agreement with Fujifilm

Regeneron (REGN) announced an expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of Regeneron’s commercial biologic medicines at their Holly Springs, North Carolina, campus. Regeneron will nearly double its U.S. large-scale manufacturing capacity by accessing Fujifilm’s new biopharmaceutical facility. With technology transfer beginning immediately and a ten-year term, the total investment is estimated to exceed $3B. Regeneron continues to invest in its New York State operations, where an approximately $3.6B expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities. In addition, the company is constructing a brand new fill/finish manufacturing facility in Rensselaer, New York, and has acquired an over 1 million-square foot property in Saratoga Springs, New York, for production support activities and, potentially, additional manufacturing capacity. Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing are expected to total more than $7B.